Ming‐Shi Chang

Tulane University — United States

Medicine · Health Sciences

22h-index8.3kcitations68works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(23), Psoriasis: Treatment and Pathogenesis(19), Cytokine Signaling Pathways and Interactions(13), Cancer Research and Treatments(8), Bone Metabolism and Diseases(6)

Publications67 total

Therapeutic appraisal in protracted heart failure
The American Journal of the Medical Sciences·2025
The effects of zoledronic acid treatment and endurance exercise on ovariectomy-induced osteopenia in Wistar rats
Sport Sciences for Health·2024
Deficiency of IL-20 receptor subunit A decreases enterovirus A71 lethality of mice with enhanced M1 macrophage polarization and cytokine
Research Square (Research Square)·2024Open Access
Supplementary Figure 1 from Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth
2023Open Access
Supplementary Figure 1 from Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth
2023Open Access
Data from Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth
2023Open Access
Supplementary Figure Legend from Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth
2023Open Access
Supplementary Figure Legend from Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth
2023Open Access
Data from Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth
2023Open Access
Supplementary Figure 3 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Figure 1 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Table 3 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Table 2 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Figure Legends 1-3 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Table 3 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Table 4 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Table 1 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Data from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Figure 1 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
Supplementary Figure 2 from Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Yu‐Hsiang Hsu(13), Chung‐Hsi Hsing(10), Chien-Hui Chan(10), Chien‐Feng Li(9), Yu‐Hsiang Hsu(8), Hung‐Chi Cheng(8), Ching‐Hua Yeh(8), Jennifer McNinch(5), Chi-Chen Wei(4), Tsang-Hai Huang(4), I‐Ming Jou(3), Ar‐Tyan Hsu(3), Rong‐Sen Yang(3), W. Scott Simonet(2), Thomas C. Boone(2), David Lowe(2), David V. Goeddel(2), R Basu(2), Rou-Yin Hsu(2), V L Mar(2)